The expression of IL-6 and STAT3 might predict progression and unfavorable prognosis in Wilms' tumor

Biochemical and Biophysical Research Communications

Volumn 435, Issue 3, 2013, Pages 408-413

  Zhang, Li Juan ^a   Liu, Wei ^a   Gao, Ying Mao ^b   Qin, Ye Jun ^a   Wu, Rong De ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

IL 6; Invasion; Metastasis; Progression; STAT3; Wilms' tumor

Indexed keywords

INTERLEUKIN 6; STAT3 PROTEIN;

ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CHILD; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHROBLASTOMA; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCHOOL CHILD; SIGNAL TRANSDUCTION; TUMOR INVASION;

CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HUMANS; INFANT; INTERLEUKIN-6; KIDNEY NEOPLASMS; MALE; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; STAT3 TRANSCRIPTION FACTOR; WILMS TUMOR;

EID: 84878988897     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.04.102     Document Type: Article

References (25)

1. Davidoff A.M. Wilms' tumor. Curr. Opin. Pediatr. 2009, 21(3):357-364.
2. Jones K.P., Grundy P.E., Coppes M.J. Recent advances in the genetics of childhood renal cancers: a report of the 3rd international conference on the molecular and clinical genetics of childhood renal tumors, together with the Mitchell Ross symposium on anaplastic and other high risk embryonal tumors of childhood, 8-10th April 1999, Wistar Institute, Philadelphia, PA. Med. Pediatr. Oncol. 2000, 35(2):126-130.
3. Alami J., Williams B.R., Yeger H. Differential expression of E-cadherin and β catenin in primary and metastatic Wilms's tumours. Mol. Pathol. 2003, 56(4):218-225.
4. Beniers A.J., Efferth T., Fuzesi L., Granzen B., Mertens R., Jakse G. P53 expression in Wilms' tumor: a possible role as prognostic factor. Int. J. Oncol. 2001, 18:133-139.
5. Ghanem M.A., van Steenbrugge G.J., Sudaryo M.K., Mathoera R.B., Nijman J.M., van der Kwast T.H. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J. Clin. Pathol. 2003, 56(2):107-113.
6. Alami J., Williams B.R., Yeger H. Expression and localization of HGF and met in Wilms' tumours. J. Pathol. 2002, 196(1):76-84.
7. Zhu Z., Zhong S., Shen Z. Targeting the inflammatory pathways to enhance chemotherapy of cancer. Cancer Biol. Ther. 2011, 12(2):95-105.
8. Tawara K., Oxford J.T., Jorcyk C.L. Clinical significance of interleukin (IL-6) in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag. Res. 2011, 3:177-189.
9. Xie G., Yao Q., Liu Y., et al. IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures. Int. J. Oncol. 2012, 40(4):1171-1179.
10. Su Y.W., Xie T.X., Sano D., Myers J.N. IL-6 stabilizes twist and enhances tumor cell motility in head and neck cancer cells through activation of casein kinases 2. PLoS One 2011, 6(4):e19412.
11. Duffy S.A., Taylor J.M., Terrell J.E., et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 2008, 113:750-757.
12. Kita H., Shiraishi Y., Watanabe K., Suda K., Ohtsuka K., Koshiishi Y., Goya T. Does postoperative serum interleukin-6 influence early recurrence after curative pulmonary resection of lung cancer?. Ann. Thorac. Cardiovasc. Surg. 2011, 17(5):454-460.
13. Knupfer H., Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res. Treat. 2007, 102(2):129-135.
14. Knuper H., Preiss R. Serum interleukin-6 levels in colorectal cancer patients-a summary of published results. Int. J. Colorectal Dis. 2010, 25(2):135-140.
15. Friedrichs K., Gluba S., Eidtrnann H., Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer 1993, 72:3641-3647.
16. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119:1420-1428.
17. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation and cancer. Cell 2010, 140:883-899.
18. Groen H.J., Sietsma H., Vincent A., Hochstenbag M.M., van Putten J.W., van den Berg A. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J. Clin. Oncol. 2011, 29(32):4320-4326.
19. Pine S.R., Mechanic L.E., Enewold L., et al. Increased levels of circulating interleukin 6, interleukin C-reactive protein, and risk of lung cancer. J. Natl. Cancer Inst. 2011, 103(14):1112-1122.
20. Grivennikov S., Karin M. Autocrine IL-6 signaling: A key event in tumorigenesis?. Cancer Cell 2008, 13:7-9.
21. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Eng. J. Med. 2012, 366(10):883-892.
22. Wallner L., Dai J., Escara-Wilke J., et al. Inhibition of interleukin-6 with CNTO328, an anti-interleukin- 6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res. 2006, 66:3087-3095.
23. Dorff T.B., Goldman B., Pinski J.K., et al. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin. Cancer Res. 2010, 16:3028-3034.
24. Page B.D., Ball D.P., Gunning P.T. Signal transducer and activator of transcription 3 inhibitors: a patent review. Expert Opin. Ther. Pat. 2011, 21(1):65-83.
25. Boehm A.L., Sen M., Seethala R., et al. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol. Pharmacol. 2008, 73:1632-1642.